{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.12","upperLimit":"2.86","value":"1.74"},{"groupId":"OG001","lowerLimit":"0.62","upperLimit":"1.51","value":"1.30"},{"groupId":"OG002","lowerLimit":"0.59","upperLimit":"4.04","value":"0.76"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"description":"PFS was defined as the time from the first dose date to the date of PD or date of death (whichever occurred first). PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions was also considered progression). Data for this secondary endpoint was collected and analyzed up to the primary completion date (PCD). As there was no further data collected, therefore data is reported till PCD only.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pediatric participants with RMS received eribulin mesylate as an IV infusion on Days 1 and 8 of each 21-day cycle at a dose of 1.4 mg/m\\^2. Participants continued to receive study therapy until progression of disease, (per RECIST 1.1), exhibited no clinical benefit, intolerable toxicity, withdrawal of consent or termination of the study program, whichever occurred first.","id":"OG000","title":"Eribulin Mesylate 1.4 mg/m^2: RMS"},{"description":"Pediatric participants with non-rhabdomyosarcoma solid tumor sarcoma (NRSTS) received eribulin mesylate as an IV infusion on Days 1 and 8 of each 21-day cycle at a dose of 1.4 mg/m\\^2. Participants continued to receive study therapy until progression of disease, (per RECIST 1.1), exhibited no clinical benefit, intolerable toxicity, withdrawal of consent or termination of the study program, whichever occurred first.","id":"OG001","title":"Eribulin Mesylate 1.4 mg/m^2: NRSTS"},{"description":"Pediatric participants with EWS received eribulin mesylate as an IV infusion on Days 1 and 8 of each 21-day cycle at a dose of 1.4 mg/m\\^2. Participants continued to receive study therapy until progression of disease, (per RECIST 1.1), exhibited no clinical benefit, intolerable toxicity, withdrawal of consent or termination of the study program, whichever occurred first.","id":"OG002","title":"Eribulin Mesylate 1.4 mg/m^2: EWS"}],"paramType":"MEDIAN","populationDescription":"The FAS included all participants who receive at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"From the time from the first dose date to the date of disease progression (PD) or date of death, whichever occurred first (up to approximately 32 months)","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}